Neogenomics Inc reports results for the quarter ended December 31 - Earnings Summary

• Neogenomics Inc NEO.OQ reported quarterly adjusted earnings of 4 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of 3 cents. The mean expectation of fifteen analysts for the quarter was for earnings of 3 cents per share. Wall Street expected results to range from 1 cents to 7 cents per share.

• Revenue rose 10.6% to $172.00 million from a year ago; analysts expected $173.18 million.

• Neogenomics Inc's reported EPS for the quarter was a loss of 12 cents​.

• The company reported a quarterly loss of $15.32 million.

• Neogenomics Inc shares had fallen by 12.5% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 8.1% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the healthcare facilities & services peer group is also "buy"

Wall Street's median 12-month price target for Neogenomics Inc is $19.00

This summary was machine generated from LSEG data February 18 at 02:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)